Radiation protection considerations with [⁸⁹Zr]Zr-girentuximab PET and surgery.

IF 3.1 3区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

EJNMMI Research Pub Date : 2025-05-23 DOI:10.1186/s13550-025-01247-1

Adnan Chowdhury, Clément Morgat, Clement Bailly, John Sunderland, Stephen A Graves, Andrew M Scott, Sean Baker, Beverley F Holman

{"title":"Radiation protection considerations with [89Zr]Zr-girentuximab PET and surgery.","authors":"Adnan Chowdhury, Clément Morgat, Clement Bailly, John Sunderland, Stephen A Graves, Andrew M Scott, Sean Baker, Beverley F Holman","doi":"10.1186/s13550-025-01247-1","DOIUrl":null,"url":null,"abstract":"Background: 89Zr is emerging as a popular positron-emitting radionuclide for imaging; however, its 909 keV gamma emission presents shielding challenges, and radiation exposure safety guidelines for healthcare professionals working with the radionuclide have not been well-established. To guide assessment of the radiation risk and necessary safety guidelines, we present laboratory dose rate measurements of 89Zr syringes and vials, and dose rates measurements made during the ZIRCON clinical trial ([89Zr]Zr-girentuximab) to evaluate healthcare provider exposure during administration, imaging, and surgical procedures.Results: The maximum dose rate from a vial with no shielding was 0.334 µSv/h/MBq, and the minimum dose rate with 66 mm lead shielding was 0.004 µSv/h/MBq. The controlled spill measured 0.52 µSv/h/MBq. Dose rates 1 m from patients who received [89Zr]Zr-girentuximab had an average of 3.90 µSv/h at imaging. During surgery, waste measured below background levels, and a bed assistant 0.8 m from the patient received a 5 µSv/h whole-body dose rate. The excised kidney measured 6 µSv/h at 5 cm.Conclusions: Our results demonstrate low radiation exposure levels associated with 89Zr handling and exposure to the patient. With potential integration of 89Zr into clinical practice, appropriate radiation safety guidelines are needed. Dose rate measurements can help guide development of best practices and site-specific protocols.Clinical trial number: not applicable for this study; ZIRCON trial number NCT03849118, registered on 19 February 2019.","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"59"},"PeriodicalIF":3.1000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12102418/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13550-025-01247-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Background: ⁸⁹Zr is emerging as a popular positron-emitting radionuclide for imaging; however, its 909 keV gamma emission presents shielding challenges, and radiation exposure safety guidelines for healthcare professionals working with the radionuclide have not been well-established. To guide assessment of the radiation risk and necessary safety guidelines, we present laboratory dose rate measurements of ⁸⁹Zr syringes and vials, and dose rates measurements made during the ZIRCON clinical trial ([⁸⁹Zr]Zr-girentuximab) to evaluate healthcare provider exposure during administration, imaging, and surgical procedures.

Results: The maximum dose rate from a vial with no shielding was 0.334 µSv/h/MBq, and the minimum dose rate with 66 mm lead shielding was 0.004 µSv/h/MBq. The controlled spill measured 0.52 µSv/h/MBq. Dose rates 1 m from patients who received [⁸⁹Zr]Zr-girentuximab had an average of 3.90 µSv/h at imaging. During surgery, waste measured below background levels, and a bed assistant 0.8 m from the patient received a 5 µSv/h whole-body dose rate. The excised kidney measured 6 µSv/h at 5 cm.

Conclusions: Our results demonstrate low radiation exposure levels associated with ⁸⁹Zr handling and exposure to the patient. With potential integration of ⁸⁹Zr into clinical practice, appropriate radiation safety guidelines are needed. Dose rate measurements can help guide development of best practices and site-specific protocols.

Clinical trial number: not applicable for this study; ZIRCON trial number NCT03849118, registered on 19 February 2019.

查看原文本刊更多论文

[89Zr] zr -吉伦妥昔单抗PET与手术的辐射防护考虑。

背景：89Zr是一种流行的正电子放射成像核素；然而，它的909kev伽马辐射带来了屏蔽方面的挑战，并且针对使用放射性核素的医疗保健专业人员的辐射暴露安全指南尚未建立。为了指导辐射风险评估和必要的安全指南，我们提供了89Zr注射器和小瓶的实验室剂量率测量，以及ZIRCON临床试验（[89Zr]Zr-girentuximab）期间的剂量率测量，以评估医疗保健提供者在给药、成像和外科手术过程中的暴露。结果：无屏蔽时的最大剂量率为0.334µSv/h/MBq，有66 mm铅屏蔽时的最小剂量率为0.004µSv/h/MBq。可控泄漏量为0.52µSv/h/MBq。接受[89Zr]Zr-girentuximab治疗的患者的剂量率为1 m，成像时平均为3.90µSv/h。手术期间，测量到的废物低于背景水平，距离患者0.8 m的病床助理接受了5µSv/h的全身剂量率。切除的肾脏在5cm处测量6µSv/h。结论：我们的研究结果表明，低辐射暴露水平与89Zr处理和暴露于患者有关。随着89Zr可能融入临床实践，需要适当的辐射安全指南。剂量率测量有助于指导制定最佳做法和特定场址方案。临床试验号：不适用本研究；锆石试验号NCT03849118，注册于2019年2月19日。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EJNMMI Research RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING&nb-

CiteScore

5.90

自引率

3.10%

发文量

审稿时长

13 weeks

期刊介绍： EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies. The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.